Brookstone Capital Management Trims Stock Holdings in CVS Health Corporation $CVS

Brookstone Capital Management reduced its holdings in shares of CVS Health Corporation (NYSE:CVS) by 15.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 30,368 shares of the pharmacy operator’s stock after selling 5,746 shares during the period. Brookstone Capital Management’s holdings in CVS Health were worth $2,181,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of CVS Health by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 120,709,530 shares of the pharmacy operator’s stock valued at $9,579,508,000 after purchasing an additional 1,824,424 shares during the period. Capital World Investors increased its stake in CVS Health by 2.1% in the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock worth $5,155,380,000 after buying an additional 1,419,575 shares during the period. State Street Corp lifted its holdings in CVS Health by 2.1% during the 4th quarter. State Street Corp now owns 60,183,743 shares of the pharmacy operator’s stock valued at $4,776,182,000 after buying an additional 1,245,457 shares in the last quarter. Capital International Investors lifted its holdings in CVS Health by 3.4% during the 4th quarter. Capital International Investors now owns 27,592,356 shares of the pharmacy operator’s stock valued at $2,189,793,000 after buying an additional 900,153 shares in the last quarter. Finally, Invesco Ltd. boosted its position in CVS Health by 3.2% in the 3rd quarter. Invesco Ltd. now owns 24,293,058 shares of the pharmacy operator’s stock valued at $1,831,454,000 after buying an additional 760,579 shares during the period. Institutional investors own 80.66% of the company’s stock.

Insider Activity at CVS Health

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the transaction, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Tilak Mandadi sold 69,551 shares of CVS Health stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Truist Financial raised their target price on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research report on Monday, June 1st. Weiss Ratings restated a “hold (c)” rating on shares of CVS Health in a report on Friday, May 8th. UBS Group lifted their target price on CVS Health from $100.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Mizuho increased their price target on CVS Health from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Finally, Sanford C. Bernstein raised their price target on CVS Health from $94.00 to $106.00 and gave the company an “outperform” rating in a research note on Tuesday, May 12th. Twenty-two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, CVS Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $101.28.

CVS Health Trading Up 0.5%

CVS Health stock opened at $102.04 on Thursday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The stock has a market cap of $130.19 billion, a PE ratio of 44.95, a price-to-earnings-growth ratio of 0.99 and a beta of 0.62. The stock has a 50-day moving average of $90.69 and a two-hundred day moving average of $82.04. CVS Health Corporation has a one year low of $58.50 and a one year high of $103.12.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The business had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, research analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding its direct-to-consumer GLP-1 weight-loss program and stepping up support for GLP-1 customers, which could open a new revenue stream and deepen its consumer health business. CVS expands direct-to-consumer GLP-1 weight-loss program
• Positive Sentiment: CVS also continues to get attention from investors and value-focused analysts, which can support sentiment around the stock. CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Coverage noting CVS as a top-ranked value stock may reinforce the company’s defensive appeal, but it does not appear to be a major new catalyst on its own. CVS Health (CVS) is a Top-Ranked Value Stock: Should You Buy?
• Neutral Sentiment: CVS’s community and health-awareness announcements, including an HIV-awareness message and a New Jersey grand opening, are supportive of brand image but are unlikely to materially move the stock. Why CVS Stock Trounced the Market Today
• Negative Sentiment: Florida’s attorney general subpoenaed CVS Health and launched an investigation into alleged anticompetitive pharmacy practices, adding legal and regulatory overhang. Florida Attorney General Issues Subpoena to CVS Health in Pharmacy Probe
• Negative Sentiment: Related reports about the Florida AG probe and alleged anticompetitive behavior reinforce concern that CVS could face scrutiny, legal costs, or operational changes. Florida AG to probe CVS for anticompetitive pharmacy practices

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.